3 Cardiac and Gastro Brands Specialist, Chronic Therapy Company and Respiratory and Anti-Infective Leader Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Eris Lifesciences and Cipla

Cardiac, respiratory and chronic pharma stocks give investors a way to track businesses that sit close to everyday demand in India. JB Chemicals and Pharmaceuticals, Eris Lifesciences and Cipla cover a cardiac and gastro brands specialist, a chronic therapy company and a respiratory and anti-infective leader.

This list covers three cardiac, respiratory and chronic pharma stocks with complete current figures: JB Chemicals and Pharmaceuticals, Eris Lifesciences and Cipla. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Cardiac, Respiratory and Chronic Pharma Stocks?

Cardiac, respiratory and chronic pharma stocks are listed drug makers with strong brands in heart, stomach, diabetes and respiratory care. Their earnings depend on prescriptions, new launches, export approvals and pricing.

Cardiac, Respiratory and Chronic Pharma Stocks at a Glance

On valuation, Eris Lifesciences and Cipla trade at a P/E below the industry P/E, while JB Chemicals and Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing cardiac, respiratory and chronic pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Cardiac, Respiratory and Chronic Pharma Stocks Have a Strong Roadmap in India?

Cardiac, respiratory and chronic pharma stocks have a strong roadmap in India because rising chronic disease cases and better access to care keep lifting demand for trusted prescription brands.

• Chronic therapies. Heart, diabetes and respiratory care need long-term treatment.
• Doctor trust. Established brands retain loyal prescribers.
• Global reach. Respiratory and anti-infective exports widen markets.

Why JB Chemicals and Pharmaceuticals Features Among These Cardiac, Respiratory and Chronic Pharma Stocks

Among the cardiac, respiratory and chronic pharma stocks on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.

Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.

The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8.

Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.

Why Eris Lifesciences Features Among These Cardiac, Respiratory and Chronic Pharma Stocks

Among the chronic and acute therapy company shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Cipla Features Among These Cardiac, Respiratory and Chronic Pharma Stocks

Among the three companies on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.

Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%.

In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.

Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

What to watch: Follow new product launches in the United States and the growth of key domestic brands.

JB Chemicals and Pharmaceuticals vs Eris Lifesciences vs Cipla on Key Financials

The table below sets the three cardiac, respiratory and chronic pharma stocks side by side on revenue, profit and margin, using reported figures.

JB Chemicals and Pharmaceuticals posts the highest return on equity in this group at 17.1%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with cardiac, respiratory and chronic pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Cardiac, Respiratory and Chronic Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these cardiac, respiratory and chronic pharma stocks, the main points are: Long-term chronic and acute therapy company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Price controls. Government pricing rules can affect some medicines.
• Competition. Many companies compete for doctor attention.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter cardiac, respiratory and chronic pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Cardiac, Respiratory and Chronic Pharma Stocks

Cardiac, respiratory and chronic pharma stocks work best when investors track growth, valuation and return on equity side by side. JB Chemicals and Pharmaceuticals, Eris Lifesciences and Cipla each have a clear plan to expand. Based on the 23 October 2026 close, JB Chemicals and Pharmaceuticals trades at Rs 2,408.9, Eris Lifesciences at Rs 1,095.5 and Cipla at Rs 1,338.

Download the Univest iOS App or Univest Android App to track cardiac, respiratory and chronic pharma stocks, set price alerts and get research-backed stock ideas.

What are cardiac, respiratory and chronic pharma stocks?

Ans. Cardiac, respiratory and chronic pharma stocks are listed drug makers with strong brands in heart, stomach, diabetes and respiratory care. Their earnings depend on prescriptions, new launches, export approvals and pricing. This list looks at three of them, JB Chemicals and Pharmaceuticals, Eris Lifesciences and Cipla, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.

Which cardiac, respiratory and chronic pharma stocks are covered in this list?

Ans. This list covers JB Chemicals and Pharmaceuticals, Eris Lifesciences and Cipla. Based on the 23 October 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Eris Lifesciences at Rs 1,095.5 and Cipla at Rs 1,338. Their return on equity ranges from 11.3% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 22.9%.

Why do cardiac, respiratory and chronic pharma stocks have a strong future roadmap in India?

Ans. Cardiac, respiratory and chronic pharma stocks have a strong roadmap in India because rising chronic disease cases and better access to care keep lifting demand for trusted prescription brands. The main drivers are as follows. Chronic therapies. Heart, diabetes and respiratory care need long-term treatment. Doctor trust. Established brands retain loyal prescribers. Global reach. Respiratory and anti-infective exports widen markets. Together these factors give the companies on this list a visible path for growth over the coming years.

How has JB Chemicals and Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Cipla performed financially?

Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

What risks should investors check before buying cardiac, respiratory and chronic pharma stocks?

Ans. Investors should check a few risks before buying cardiac, respiratory and chronic pharma stocks. Price controls. Government pricing rules can affect some medicines. Competition. Many companies compete for doctor attention. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of cardiac, respiratory and chronic pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.